ArticleIndian dermatology online journal
Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).
Article in Indian dermatology online journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Emerging Terbinafine Resistant Trichophyton Dermatophytosis, Testing Options and Alternative Treatments: A Systematic Review.The Australasian journal of dermatology · 2025Pooled it
- Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial.Drug design, development and therapy · 2023Trial
- Evaluation of Clinicians' Knowledge of Terbinafine-resistant Extensive Dermatophytosis in France.Acta dermato-venereologica · 2026Article
- Trichophyton indotineae: Rise, Diagnosis, Treatment, and Future Directions.American journal of clinical dermatology · 2026Review
- The natural history and evolution of dermatophytosis: Host immunity in acute and chronic infection.PLoS pathogens · 2026Article
- Impacts of Competitive a Health Professionals Education Partnership Initiatives Small Grant Award on Junior Faculty Researchers: A Cross-Sectional Study.Health science reports · 2026Article
- Terbinafine-Resistant Trichophyton Dermatophytosis in Australia.The Australasian journal of dermatology · 2026Article
- Article
- Global Emergence ofInfection and drug resistance · 2026Review
- Dual therapy with minocycline and itraconazole as a new treatment option for recurrent dermatophytosis.Postepy dermatologii i alergologii · 2026Article
- Resistance & virulence traits in dermatophytes isolated from Mangaluru, India.The Indian journal of medical research · 2025Article
- An international survey of recalcitrant and recurrent tinea of the glabrous skin-A potential indicator of antifungal resistance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- NEXTODERM: Consensus on Dermatophytosis Diagnosis and Management in Nepal.Dermatology research and practice · 2025Review
- Response to "Clinico-mycological and therapeutic updates on cutaneous dermatophytic infections in the era of Trichophyton indotineae"; Focus on griseofulvin.Journal of the American Academy of Dermatology · 2025Article
- Microbial nanotechnology for agriculture, food, and environmental sustainability: Current status and future perspective.Folia microbiologica · 2024Review
- Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance.American journal of clinical dermatology · 2024Review
- Diagnosis of a recurred lesion in dermatophytosis patients after 2 weeks of antifungal therapy: A prospective observational study.Journal of family medicine and primary care · 2024Article
- Towards an Early Clinical and Biological Resistance Detection in Dermatophytosis: About 2 Cases ofJournal of fungi (Basel, Switzerland) · 2023Article
- Comparative Efficacy of Super Bioavailable Itraconazole Capsules 50 mg vs 65 mg Twice Daily in the Management of Glabrous Tinea.Infection and drug resistance · 2023Article
- A Review of Antifungal Susceptibility Testing for Dermatophyte Fungi and It's Correlation with Previous Exposure and Clinical Responses.Journal of fungi (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsDermatophytosis has always been a common superficial mycosis in India. However, the past 6-7 years have seen an unprecedented increase in the number of patients affected by recurrent, chronic, recalcitrant and steroid modified dermatophytosis involving the glabrous skin (tinea corporis, tinea cruris and tinea faciei). Importantly, there has been a notable decrease in clinical responsiveness to commonly used antifungals given in conventional doses and durations resulting in difficult-to-treat infections. Considering that scientific data on the management of the current epidemic of dermatophytosis in India are inadequate, the Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task force Against Recalcitrant Tinea (ITART) has formulated a consensus statement on the management of dermatophytosis in India.
methodsSeventeen dermatologists with a focussed interest in dermatophytosis participated in a Delphi consensus method, conducted in three rounds. They responded as either "agree" or "disagree" to 132 statements prepared by the lead experts and gave their comments. Consensus was defined as an agreement of 80% or higher concurrence. Statements on which there was no consensus were modified based on the comments and were then recirculated. The results were finally analysed in a face-to-face meeting and the responses were further evaluated. A draft of the consensus was circulated among the participants and modified based on their inputs.
resultsConsensus was achieved on 90 of the 132 statements. Direct microscopy using potassium hydroxide mount was recommended in case of diagnostic difficulty on clinical examination. Counselling of patients about strict adherence to general measures and compliance to treatment was strongly recommended as the key to successful management of dermatophytosis. A combination of systemic and topical antifungal drugs was recommended for the treatment of glabrous tinea in the current scenario. Topical corticosteroid use, whether used alone or in combination with other components, was strongly discouraged by all the experts. It was suggested that topical antifungals may be continued for 2 weeks beyond clinical resolution. Itraconazole and terbinafine were recommended to be used as the first line options in systemic therapy, whereas griseofulvin and fluconazole are alternatives. Terbinafine was agreed to be used as a first line systemic agent in treatment naïve and terbinafine naïve patients with glabrous tinea. Regular follow-up of patients to ensure compliance and monitoring of clinical response was recommended by the experts, both during treatment and for at least 4 weeks after apparent clinical cure. Longer duration of treatment was recommended for patients with chronic, recurrent and steroid modified dermatophytosis.
conclusionConsensus in the management of dermatophytosis is necessary in the face of conventional regimens proving ineffective and dearth of clinical trials re-evaluating the role of available antifungals in the wake of evolving epidemiology of the infection in the country. It needs to be backed by more research to provide the required level of evidence. It is hoped that this consensus statement improves the quality of care for patients with dermatophytosis, which has emerged as a huge public health problem, imposing considerable financial burden on the country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.